Can­cer pow­er­house As­traZeneca rolls the dice on a $75M cash bet on a buzzy up­start in the on­col­o­gy field

Af­ter es­tab­lish­ing it­self in the front ranks of can­cer drug de­vel­op­ers and mar­keters, As­traZeneca is putting its sci­en­tif­ic shoul­der — and a sig­nif­i­cant amount of cash …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER